AdvanTIG-105: Phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors.

被引：0

作者：

Frentzas, Sophia

Meniawy, Tarek

Kao, Steven Chuan-Hao

Wang, Ruihua

Zuo, Yunxia

Zheng, Hao

Tan, Wei

机构：

[1] Monash Hlth, Med Oncol, Melbourne, Vic, Australia

[2] Monash Univ, Sch Med & Hlth Sci, Melbourne, Vic, Australia

[3] Edith Cowan Univ, Joondalup, WA, Australia

[4] Univ Western Australia, Sch Med, Crawley, WA, Australia

[5] Sir Charles Gairdner Hosp, Dept Med Oncol, Nedlands, WA, Australia

[6] Univ Sydney, Sch Med, Chris OBrien Life House, Sydney, NSW, Australia

[7] BeiGene Ltd, Shanghai, Peoples R China

[8] BeiGene USA Inc, San Mateo, CA USA

来源：

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.2583

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2583

引用

页数：2